ALKEM · NSE
Alkem Laboratories Limited
₹5,466.5
+2.21% (+₹118)
Prev. close
₹5,348.5
Volume
3,20,770
Delivery %
76.3%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Basudeo Narian Singh
Headquarters
Mumbai
Employees
19,346
Website
alkemlabs.comExchange
View on NSE ↗Key stats
Market cap
₹65,360.21 Cr
P/E ratio (TTM)
30.3
Dividend yield
0.37%
EPS (TTM)
₹180.24
Beta (1Y · daily vs NIFTY 50)
0.69
Beta (5Y · monthly vs NIFTY 50)
0.75
Shares float
4.61 Cr
EPS · quarter ended Jun 2026
₹43.49
Upcoming earnings
12 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹7,219.68 Cr | ₹10,634.19 Cr | ₹11,599.26 Cr | ₹12,667.58 Cr | ₹12,964.52 Cr | ₹14,712.27 Cr | |
| EBITDA | ₹2,126.16 Cr | ₹2,200.61 Cr | ₹1,722.55 Cr | ₹2,434.84 Cr | ₹3,005.89 Cr | ₹3,413.73 Cr |
| ₹1,685.08 Cr | ₹1,645.62 Cr | ₹984.17 Cr | ₹1,795.77 Cr | ₹2,165.48 Cr | ₹2,301.80 Cr | |
| Diluted EPS | ₹140.93 | ₹137.63 | ₹82.31 | ₹150.19 | ₹181.11 | ₹192.51 |
Net income for Mar 2021 could not be independently verified against the company's own annual report: this page shows ₹1,685.08 Cr while the annual report gives ₹1,617.77 Cr (4.0% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹1,149.31 Cr) is left blank here too, rather than shown from only one of the two sources.
EBITDA for Mar 2021 could not be independently verified against the company's own annual report: this page shows ₹2,126.16 Cr while the annual report gives ₹2,175.60 Cr (2.3% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹1,577.61 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹11,519.26 Cr | ₹14,069.19 Cr | ₹13,757.00 Cr | ₹15,575.00 Cr | ₹17,691.00 Cr | ₹20,858.00 Cr | |
| ₹1,791.98 Cr | ₹2,668.19 Cr | ₹1,396.68 Cr | ₹1,418.41 Cr | ₹1,380.90 Cr | ₹2,047.16 Cr | |
| Stockholders' equity | ₹7,376.73 Cr | ₹8,637.90 Cr | ₹9,045.00 Cr | ₹10,312.00 Cr | ₹11,985.00 Cr | ₹13,820.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,324.48 Cr | ₹1,111.02 Cr | ₹1,682.00 Cr | ₹1,948.00 Cr | ₹1,913.00 Cr | ₹1,963.00 Cr | |
| Investing cash flow | ₹-1,120.99 Cr | ₹-1,435.13 Cr | ₹112.84 Cr | ₹-1,008.51 Cr | ₹-1,298.76 Cr | ₹-1,667.21 Cr |
| ₹-208.96 Cr | ₹379.57 Cr | ₹-1,761.00 Cr | ₹-1,145.00 Cr | ₹-811.00 Cr | ₹-503.00 Cr | |
| Capital expenditure | ₹-195.00 Cr | ₹-338.88 Cr | ₹-233.00 Cr | ₹-259.00 Cr | ₹-676.00 Cr | ₹-617.00 Cr |
| End cash position | ₹15.22 Cr | ₹232.18 Cr | ₹273.80 Cr | ₹66.31 Cr | ₹-120.09 Cr | ₹-342.13 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22 | Sep 22–Jun 23(4Q) | Sep 23–Mar 24(3Q) | Jun 24 | Sep 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25–Mar 26(3Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 58.84% | 57.13% | 57.14% | 57.16% | 56.74% | 56.38% | 55.66% | 55.13% | 53.04% | 51.20% | 49.70% |
| Public | 41.16% | 42.87% | 42.86% | 42.84% | 43.26% | 43.62% | 44.34% | 44.87% | 46.96% | 48.80% | 50.30% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Alkem Laboratories Limited | ₹63,949.34 Cr | ₹5,466.5 | 29.6 | 4.63 | 16.7% | 0.15 | +13.5% | -0.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Show all 14
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
45 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.